TAYLOR SWIFT | THE ERAS TOUR Concert Film Crosses $100 Million in Global Advance Ticket Sales Revenue More Than a Week Before the Movie Debuts at More Than 8,500 Theatres in 100 Countries Worldwide on Friday, October 13
AMC Theatres Distribution and AMC Entertainment® (NYSE:AMC), the largest theatrical exhibitor in the United States and the world, today announced that as of October 4, TAYLOR SWIFT | THE ERAS TOUR concert film had sold more than $100 million in advance tickets globally. On October 13, TAYLOR SWIFT | THE ERAS TOUR concert film will start playing in most of the confirmed 8,500 theatres across 100 countries around the world.
Audience demand for TAYLOR SWIFT | THE ERAS TOUR concert film has been incredible from the moment it was first announced. It took less than 24 hours for the TAYLOR SWIFT | THE ERAS TOUR concert film to shatter AMC’s U.S. record for the highest ticket-sales revenue during a single day in AMC’s 103-year history. Advanced ticket sales are strong across the United States, from the largest cities to the smallest towns, and are particularly strong in premium large-screen formats like IMAX, Dolby Cinema, PRIME at AMC and other branded premium experiences.
AMC and its sub-distribution partners Variance Films in the United States, Cineplex in Canada, Cinepolis in Mexico and Central America, and Trafalgar Releasing outside of North America, have responded to broad cinema operator interest in playing TAYLOR SWIFT | THE ERAS TOUR concert film and confirmed more than 8,500 theatres across 100 countries worldwide. AMC and its sub-distribution partners continue to take steps to reach agreements with additional cinema operators throughout the world to play this spectacular Taylor Swift tour-de-force.
TAYLOR SWIFT | THE ERAS TOUR concert film will play at least four showtimes per day on Thursdays, Fridays, Saturdays, and Sundays at all AMC locations in the U.S. It will also play at every ODEON Cinemas location in Europe. For U.S. fans interested in experiencing the concert film at AMC Theatres, tickets are available at amctheatres.com/TheErasTour
Moviegoers wanting to purchase tickets to other movie theatres in the United States and around the world can find more information and showtimes at TSTheErasTourFilm.com.
About AMC Entertainment Holdings, Inc.
AMC is the largest movie exhibition company in the United States, the largest in Europe and the largest throughout the world with approximately 900 theatres and 10,000 screens across the globe. AMC has propelled innovation in the exhibition industry by: deploying its Signature power-recliner seats; delivering enhanced food and beverage choices; generating greater guest engagement through its loyalty and subscription programs, website, and mobile apps; offering premium large format experiences and playing a wide variety of content including the latest Hollywood releases and independent programming. For more information, visit www.amctheatres.com.
Category: Company Release
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231005259418/en/
Contact information
Ryan Noonan, (913) 213-2183
rnoonan@amctheatres.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Published Data Confirms Nemluvio ® (Nemolizumab) Can Rapidly Relieve Itch and Improve Sleep in as Early as Two Days in Both Atopic Dermatitis and Prurigo Nodularis17.12.2025 07:00:00 CET | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today released new clinical data confirming nemolizumab’s rapid onset of action on itch and sleep, with significant improvements observed as early as 48 hours after treatment in some patients with atopic dermatitis and prurigo nodularis.1 The findings from post-hoc analyses of the phase III ARCADIA and OLYMPIA clinical trial programs were published in the Journal of the European Academy of Dermatology and Venereology. Nemolizumab is the first approved monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signalling of IL-31.2,5,6 IL-31 is a neuroimmune cytokine that drives itch and other symptoms in both atopic dermatitis and prurigo nodularis.3,4 These new findings reinforce the critical role of IL-31 pathway inhibition in achieving rapid itch response. Atopic dermatitis and prurigo nodularis are debilitating skin conditions that significantly affect quality of life, with symptoms such as per
Mori Memorial Foundation’s Global Power City Index 2025 Sees City Rankings Shift Due to Tourism Gains in East Asia and Inflationary Pressures in the West17.12.2025 04:00:00 CET | Press Release
The Mori Memorial Foundation’s Institute for Urban Strategies, a research body established by Mori Building, Tokyo’s leading urban landscape developer, today published its annual Global Power City Index (GPCI) 2025, a report evaluating the urban competitiveness of 48 major cities worldwide. The report also includes the GPCI–Financial Centers index, an assessment of cities as international financial centers, and the new GPCI–Startup Ecosystems index, which assesses the competitiveness of startup environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216187692/en/ 48 Major Cities Evaluated in Mori Memorial Foundation’s GPCI-2025 Report This year’s report highlights the remarkable rise of East Asian cities and the stagnation of several Western cities, showing how global challenges, such as geopolitical tensions and regional disparities in inflation, are greatly impacting the performance of major cities worldwide. The r
GE HealthCare and Indonesia’s Ministry of Health to expand access to quality care through the provision of 300+ advanced CT scanners17.12.2025 03:00:00 CET | Press Release
GE HealthCare (Nasdaq: GEHC) today announced it will supply more than 300 CT (computed tomography) scanners under Indonesia’s Strengthening Indonesia’s Health Referral Network (SIHREN) program to deliver equitable, high-quality care to more than 280 million Indonesians. As part of a competitively awarded, multi-year contract, GE HealthCare will supply the advanced CT scanners to public hospitals across all 38 provinces, including urban and remote areas. The CT scanner procurement under SIHREN was conducted through a fully competitive international tender process governed by the World Bank’s procurement regulations. SIHREN is the largest healthcare infrastructure investment in Indonesia’s history and among the largest multilateral health projects globally. SIHREN aims to modernize the national referral system and expand access to diagnostics and treatment across the archipelago, with a focus on non-communicable diseases (NCD) management, maternal health, and pandemic resilience. By mode
IDWS 2025 Concludes with Focus on Global Knowledge Exchange, Financial Opportunities, and Scalable Water Solutions16.12.2025 20:03:00 CET | Press Release
The 4th Innovation Driven Water Sustainability Conference (IDWS) 2025 concluded on Wednesday in Jeddah, confirming its status as one of the world’s most influential platforms for shaping the future of water innovation, sustainability, and security. Gathering senior global policymakers and international industry leaders, this year’s edition has advanced critical dialogue on safeguarding the planet’s most vital resource, with Saudi Arabia at the forefront. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216483490/en/ Investors, innovators, and global institutions gather in Saudi to outline how capital, collaboration, and governance can accelerate long term water sustainability (Photo: AETOSWire) Among the most consequential engagements were a series of meetings that brought together discussions powered by SWA, centred on shared challenges, knowledge exchange, and exploring opportunities within the global water ecosystem. Att
OAG Appoints ex-Skyscanner Executive Filip Filipov as New Chief Executive Officer16.12.2025 17:00:00 CET | Press Release
OAG announces today the appointment of Filip Filipov, ex-Skyscanner executive, as new Chief Executive Officer. Filip Filipov currently serves as the company’s Chief Operating Officer and takes over from Phil Callow who has chosen to step down having completed thirteen transformational years at the helm of OAG to pursue his many other interests. Since joining in 2024, Filipovhas played a leading role in the company’s ambitious next phase of growth and ongoing acceleration. He will now lead OAG into a new era defined by advanced data products and AI-driven intelligence. Before joining OAG, Filipov held senior roles in travel technology and big-data consulting, including on Skyscanner’s executive team. Filip Filipov said: “It’s a privilege to step into this role and lead a company with such a strong heritage and reputation. I’m excited for what’s ahead and committed to serving our customers with the reliability, service, and innovation they depend on.” Chairman of OAG, Gehan Talwatte, com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom